Guard Therapeutics International AB (publ) (GUARD.ST) Stock Analysis & Winston Score

Guard Therapeutics International AB is a small Swedish biotech company focused on developing drugs to protect the kidneys during medical procedures. Its lead drug candidate, ROSgard, is designed to reduce kidney damage that can occur when patients undergo heart surgery — a serious complication that affects a significant number of surgical patients each year. The company is in the clinical-stage, meaning it does not yet sell any approved products. Guard Therapeutics earns no product revenue at this stage and funds its operations through equity raises and grants, which is typical for early-stage biotech firms. It operates primarily in Sweden and conducts clinical trials across European medical centers. The company's entire value rests on the success of ROSgard in clinical development, which creates significant risk — if trials fail or regulatory approval is not obtained, the company has no fallback revenue stream. The key near-term driver is clinical trial data that will determine whether ROSgard can advance toward regulatory submission.